Amylyx Pharmaceuticals

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100k to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX

Retrieved on: 
Friday, March 29, 2024
Titan, Plaintiff, ALS, Patient, AMX0035, Class, Amylyx Pharmaceuticals, Advertising, Court

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action - AMLX

Retrieved on: 
Tuesday, March 26, 2024
Titan, Plaintiff, ALS, Patient, AMX0035, Class, Amylyx Pharmaceuticals, Advertising, Court

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX

Retrieved on: 
Saturday, March 23, 2024
Titan, Plaintiff, ALS, Patient, AMX0035, Class, Amylyx Pharmaceuticals, Advertising, Court

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX

Retrieved on: 
Thursday, March 14, 2024
Titan, Plaintiff, ALS, Patient, AMX0035, Class, Amylyx Pharmaceuticals, Advertising, Court

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline

Retrieved on: 
Monday, April 8, 2024
Amylyx Pharmaceuticals, Patient, Defendant, Apoptosis, ALS, Pharmaceutical industry

LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

AMLX DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action – AMLX

Retrieved on: 
Monday, April 8, 2024
Titan, Patient, Class, Amylyx Pharmaceuticals, Advertising, ALS, Court

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

AMLX 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action

Retrieved on: 
Sunday, April 7, 2024
Patient, SAN, News, Person, Disclosure, Amylyx Pharmaceuticals, Hagens Berman, Evercore, Pharmaceutical industry

On March 8, 2024, Amylyx announced that topline results from its Global Phase 3 PHOENIX Trial of its product intended to treat patients with Lou Gehrig’s disease -- RELYVRIO -- did not meet its primary endpoint of reaching statistical significance, “nor was there statistical significance seen in secondary endpoints.”

Key Points: 
  • SAN FRANCISCO, April 07, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now .
  • On the Nov. 9, 2023 news alone, the price of Amylyx shares crashed $5.74, or about 31% lower, on Nov. 9, 2023.
  • "We’re investigating whether the Amylyx March 8 disclosure concerning RELYVRIO may warrant extending the alleged fraudulent period,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

AMLX DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action – AMLX

Retrieved on: 
Thursday, April 4, 2024
Titan, Patient, Class, Amylyx Pharmaceuticals, Advertising, ALS, Court

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

AMLX 5-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action

Retrieved on: 
Thursday, April 4, 2024
Medication, Patient, News, Person, Disclosure, Amylyx Pharmaceuticals, Hagens Berman, Evercore, Pharmaceutical industry

On March 8, 2024, Amylyx announced that topline results from its Global Phase 3 PHOENIX Trial of its product intended to treat patients with Lou Gehrig’s disease -- RELYVRIO -- did not meet its primary endpoint of reaching statistical significance, “nor was there statistical significance seen in secondary endpoints.”

Key Points: 
  • On the Nov. 9, 2023 news alone, the price of Amylyx shares crashed $5.74, or about 31% lower, on Nov. 9, 2023.
  • "We’re investigating whether the Amylyx March 8 disclosure concerning RELYVRIO may warrant extending the alleged fraudulent period,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
  • For more information, call Reed Kathrein at 844-916-0895 or email [email protected] .

Investors who lost money on Amylyx Pharmaceuticals, Inc. (AMLX) should contact The Gross Law Firm about pending Class Action - AMLX

Retrieved on: 
Wednesday, April 3, 2024
NEXT, Amylyx Pharmaceuticals, Patient, Apoptosis, Fraud, ALS, Security (finance)

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX).

Key Points: 
  • NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX).
  • Shareholders who purchased shares of AMLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.